Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration announced today it  approved Qiagen's Therascreen FGFR RGQ RT-PCR Kit as a companion diagnostic for Janssen Pharmaceutical's metastatic bladder cancer drug erdafitinib (Balversa) in a molecularly defined subpopulation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.